Thermo Fisher Scientific’s response to COVID-19 continues to expand to support development, production of therapeutics, vaccines

Bottle of pills on a conveyor belt

Thermo Fisher Scientific Inc. (Waltham, MA) continues to expand global capacity and capabilities across its pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally.

To support accelerated vaccine development in the U.S, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), announced funding to support the expansion of Thermo Fisher’s manufacturing capacity for sterile injectables, which can be used to fill a high volume of vaccine doses.

Thermo Fisher says it is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months.

The company has also expanded capacity for customers who are developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients…

Read More